Androgens are responsible for the development and maintenance of secondary sexual characteristics, fertility, and anabolic effects of somatic tissues (lean body mass) in men. 
• Increase in muscle strength: Bhasin et al. 26 found that T supplementation for 16 weeks in 61 hypogonadal, HIV-infected men aged 18-50 years resulted in increases in muscle volume and strength, whether accompanied by resistance training or not. However, a recent study suggested that replacing testosterone, dehydroepiandrosterone (DHEA), Vijay Shivaswamy, MD, is Assistant Professor in the Division of Endocrinology at the University of Utah School of Medicine. He is a board-certified endocrinologist and has a special interest in managing patients with pituitary disorders and osteoporosis. He also has expertise in reading dual X-ray absorptiometry scans. U S E N D O C R I N E D I S E A S E 2 0 0 7 or dehydroepiandrosterone sulfate (DHEA-S) in men with baseline mid to high normal levels has little benefit on physical performance and potentially increases risk of side effects. 25 • Increase in bone mineral density (BMD) but no data on fracture risk:
Testosterone replacement has been associated with improvement of trabecular and cortical bone density of the spine in younger and older hypogonadal men.
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• Cardiovascular effects: A recent meta-analysis concluded that there is weak evidence to suggest that testosterone use in men with baseline low testosterone levels is not associated with important cardiovascular effects.
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Testosterone Replacement
Daily output of testosterone is about 4-7mg, with the concentrations being higher in the morning and lower in the evening 22 (see Table 4 ). There are a variety of formulations on the market, listed below.
Oral Preparations
The first orally active, synthesized derivative of T was 17-α-methyl-T. Blood levels peak at 1.5-2 hours and serum half-life is about 150 minutes, indicating the need for several daily doses to maintain therapeutic levels.
Side effects include cholestasis, peliosis, elevation of liver enzymes, and reduction of high-density lipoprotein-cholesterol. 5 Fluoxymesterone is a 17-alpha-methyl testosterone steroid with fluorine in the 9-position and is longer acting than its parent steroid, but is limited by hepatotoxicity. 5 Mesterolone is derived from 5-alpha-dihydrotestosterone with a methyl group in the 1-position. It is not hepatotoxic, but relatively large doses must be taken several times a day and dosing is difficult to monitor.
Testosterone undecanoate is an esterified form of testosterone, which is absorbed by lymphatics, by-passing the portal system. Serum testosterone levels tend to vary within the same individual. An advantage is oral administration, but it is not yet available in the US.
Intramuscular Preparations
Two 
Transdermal Preparations
Trans-scrotal Testosterone
Scrotal patches deliver approximately 4-6 mg of testosterone daily. 30 Normal androgen concentrations were achieved in 80% of hypogonadal men.
5
Dihydrotestosterone (DHT) levels are elevated and scrotal shaving is necessary for optimal adherence of the patch. The advantages are ease of administration and good skin tolerability.
However, there is potential for transfer of testosterone to partner by direct skin-skin contact. This can be avoided by using a barrier, such as a shirt, to cover the application site.
Buccal Preparation
The available formulation is Striant ® , which provides 30mg controlled-release used twice daily. It is applied to the depression in the gum above the upper incisors and releases testosterone into the peripheral circulation. T and DHT are normalized. Gum-related adverse effects occur in 16.3% of treated men. 
Induction of Fertility by using Human Chorionic Gonadotropin
In men with hypogonadotropic hypogonadism desiring fertility, human chorionic gonadotropin (hCG) alone or in combination with human menopausal gonatotropins (hMG) can be used to induce spermatogenesis and fertility. 23 Since hMG is expensive, hCG is the initial therapy. hCG can be given IM 1,000-2,000 units two to three times per week. Testosterone levels and sperm counts can be monitored to reach normal levels. Sperm counts lower than normal can be sufficient to induce fertility in such circumstances. If spermatogenesis/induction of fertility have not occurred after 6-12 months, hMG can be added to the regimen at doses of 75 international units (IU) IM three times a week. 23 This can be increased to 150
IU three times a week in six months, if desired results have not occurred.
Side Effects
• Erythrocytosis: This has been associated with testosterone replacement therapy, but transdermal preparations tend to have fewer cases of polycythemia compared with testosterone enanthate injections.
Erythrocytosis is correlated with elevated bioavailable testosterone and estradiol levels.
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• Acne and oily skin.
• Growth of undiagnosed prostate cancer.
• Azoospermia: When used as a means of male contraception, exogenous testosterone induces azoospermia within 10 weeks of therapy. Fertility after cessation of therapy has also been reported. 17, 18 • Changes in lipid profile: A recent meta-analysis showed that there were insignificant changes in low-density lipoprotein and thyroglobulin (Tg) levels after replacement of testosterone in men with low to low-normal testosterone. 28 • Gynecomastia. hyperplasia, even at low circulating testosterone levels. 27 • Growth of breast cancer.
• New onset or worsening of obstructive sleep apnea.
• Hepatotoxicity (oral preparations).
• Fluctuation of hypogonadal symptoms (IM preparations).
• Dermatitis (transdermal preparations).
• Potential partner testosterone transfer (gels).
• Gum irritation (buccal preparation).
Contraindications
• Prostate cancer.
• Breast cancer.
• Undiagnosed prostate nodule.
• Unexplained prostate-specific antigen (PSA) elevation.
• Erythrocytosis.
• Unstable severe congestive heart failure (class III or IV).
Monitoring
• Periodic symptomatic evaluation: Three months after beginning treatment and then annually.
• Serum testosterone levels: These can be taken 3-12hrs after applications of patch, at least a week after being on testosterone gel, and midway between injectable preparations. The goal is to maintain testosterone in the mid-normal range.
• Hemotocrit (HCT) should be checked at baseline, three months, and then annually. A patient with an HCT >55% should be evaluated for hypoxia, sleep apnea, or reduction of testosterone dosage.
• Bone mineral density measurement by dual X-ray absorptiometry should be considered one-to-two years after initiating treatment in patients with low bone mineral density.
• Digital rectal exams (DREs) and PSA level at baseline, three months, and then annually; an abnormal DRE, PSA level >4ng/ml, or increase of >1.4ng/ml warrants urological evaluation.
• Evaluated side effects related to different preparations, as detailed in the side effects section.
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